Recent Publications

Flaumenhaft Lab

1. Battinelli EM, Thon JN, Okazaki R, Peters CG, Vijey P, Wilkie AR, Noetzli LJ, Flaumenhaft R, Italiano JE. Megakaryocytes package contents into separate α-granules that are differentially distributed in platelets. Blood  Adv. 2019;3(20):3092‐3098. doi:10.1182/bloodadvances.2018020834

2. Pettinato G, Lehoux S, Ramanathan R, Salem MM, He LX, Muse O, Flaumenhaft R, et al. Generation of fully functional hepatocyte-like organoids from human induced pluripotent stem cells mixed with Endothelial Cells. Sci Rep. 2019;9(1):8920. Published 2019 Jun 20. doi:10.1038/s41598-019-45514-3

3. Göös H, Fogarty CL, Sahu B, Plagnol V, Rajamaki K, Nurmi K, Liu X, Einarsdottir E, Jouppila A, Pettersson T, Vihinen H, Krjutskov K, Saavalainen P, Jarvinen A, Muurinen M, Greco D, Scala G, Curtis J, Nordstrom D, Flaumenhaft R, et al. Gain-of-function CEBPE mutation causes noncanonical autoinflammatory inflammasomopathy. J Allergy Clin Immunol. 2019;144(5):1364‐1376. doi:10.1016/j.jaci.2019.06.003

4. Flaumenhaft R. Does GPIbα prove the allosteric disulfide bond hypothesis?. J Thromb Haemost. 2019;17(6):849‐851. doi:10.1111/jth.14428

5. Bekendam RH, Flaumenhaft R. Assays of Thiol Isomerase Enzymatic Activity. Methods Mol Biol. 2019;1967:133‐148. doi:10.1007/978-1-4939-9187-7_8

6. Eriksson O, Chiu J, Hogg PJ, Atkinson JP, Liszewski MK, Flaumenhaft R, Furie B. Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation. J Biol Chem. 2019;294(13):4878‐4888. doi:10.1074/jbc.RA118.006792

7. Higgins SJ, De Ceunynck K, Kellum JA, Chen X, Gu, X, Chaudhry SA, Schulman S, Libermann TA, Lu S, Shapiro NI, Christiani DC, Flaumenhaft R, Parikh SM. Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest. 2018;128(4):1471‐1484. doi:10.1172/JCI97488

Furie Lab

1. Bury L, Megy K, Stephens JC, Grassi L, Greene D, Gleadall N, Althaus K, Allsup D, Bariana TK, Bonduel M, Butta NV, Collins P, Curry N, Deevi SVV, Downes K, Duarte D, Elliot K, Falcinelli E, Furie B, et al. Next-generation sequencing for the diagnosis of MYH9-RD: Predicting pathogenic variants. Hum Mutat. 2020;41(1):277‐290. doi:10.1002/humu.23927

2. Eriksson O, Chiu J, Hogg PJ, Atkinson JP, Liszewski MK, Flaumenhaft R, Furie B. Thiol isomerase ERp57 targets and modulates the lectin pathway of complement activation. J Biol Chem. 2019;294(13):4878‐4888. doi:10.1074/jbc.RA118.006792

3. Eriksson O, Stopa J, Furie B. Identification of PDI Substrates by Mechanism-Based Kinetic Trapping. Methods Mol Biol. 2019;1967:165‐182. doi:10.1007/978-1-4939-9187-7_10

4. Sharda A, Furie B. Regulatory role of thiol isomerases in thrombus formation. Expert Rev Hematol. 2018;11(5):437‐448. doi:10.1080/17474086.2018.1452612

5. Peng S, Xue G, Gong L, Fang C, Chen J, Yuan C, Chen Z, Yao L, Furie B, Huang Mingdong. A long-acting PAI-1 inhibitor reduces thrombus formation. Thromb Haemost. 2017;117(7):1338‐1347. doi:10.1160/TH16-11-0891

6. Stopa JD, Baker KM, Grover SP, Flaumenhaft R, Furie B. Kinetic-based trapping by intervening sequence variants of the active sites of protein-disulfide isomerase identifies platelet protein substrates. J Biol Chem. 2017;292(22):9063‐9074. doi:10.1074/jbc.M116.771832

7. Bowley SR, Fang C, Merrill-Skoloff G, Furie BC, Furie B. Protein disulfide isomerase secretion following vascular injury initiates a regulatory pathway for thrombus formation. Nat Commun. 2017;8:14151. Published 2017 Feb 20. doi:10.1038/ncomms14151

Bauer Lab

1. Neumann I, Izcovich A, Zhang Y, Rada G, Kahn SR, Spencer F, Rezenda S, Dentali F, Bauer K, et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv. 2020;4(7):1512‐1517. doi:10.1182/bloodadvances.2019000840

2. Yang S, Bauer KA, Singleton JM, Papavassiliou E, Kramer DB. A Balancing Act. Circulation. 2020;141(13):1103‐1106. doi:10.1161/CIRCULATIONAHA.119.044780

3. Moran J, Bauer KA. Managing thromboembolic risk in patients with hereditary and acquired thrombophilias. Blood. 2020;135(5):344‐350. doi:10.1182/blood.2019000917

4. Bauer KA. How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis?. JAMA. 2020;323(2):121‐122. doi:10.1001/jama.2019.20783

5. Eche IM, Elsamadisi P, Wex N, Wyers MC, Brat GA, Cunningham K, Bauer KA. Intraoperative Unfractionated Heparin Unresponsiveness during Endovascular Repair of a Ruptured Abdominal Aortic Aneurysm following Administration of Andexanet Alfa for the Reversal of Rivaroxaban. Pharmacotherapy. 2019;39(8):861‐865. doi:10.1002/phar.2306

6. Kearon C, Parpia S, Spencer FA, Schulam S, Stevens SM, Shah V, Bauer KA, et al. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study. J Thromb Haemost. 2019;17(7):1144‐1152. doi:10.1111/jth.14458

7. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O’Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720‐728. doi:10.1056/NEJMoa1814630

Zwicker Lab

1. Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020;18(2):278‐284. doi:10.1111/jth.14671

2. Wang TF, Zwicker JI, Ay C, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17(10):1772‐1778. doi:10.1111/jth.14564

3. Zwicker JI, Muia J, Dolatshahi L, et al. Adjuvant low-dose rituximab and plasma exchange for acquired TTP. Blood. 2019;134(13):1106‐1109. doi:10.1182/blood.2019000795

4. Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight. 2019;4(4):e125851. Published 2019 Feb 21. doi:10.1172/jci.insight.125851

5. Mantia C, Zwicker JI. Anticoagulation in the Setting of Primary and Metastatic Brain Tumors. Cancer Treat Res. 2019;179:179‐189. doi:10.1007/978-3-030-20315-3_12

6. Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang T, Weitz JI, Zhang G, Zwicker JI, et al. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018;118(8):1439‐1449. doi:10.1055/s-0038-1667001

7. Samuelson Bannow BR, Lee AYY, Khorana AA, Zwicker JI, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost. 2018;2(4):664‐669. Published 2018 Jun 19. doi:10.1002/rth2.12111

Bendapudi Lab

1. Chaudhry SA, Serrata M, Tomczak L, Higgins S, Ryu J, Laprise D, Enjyoji K, Bekendam R, Kaushik V, Flaumenhaft R, Bendapudi PK. Cationic Zinc is Required for Factor XII Recruitment and Activation by Stimulated Platelets and for Thrombus Formation in vivo [published online ahead of print, 2020 Jun 16]. J Thromb Haemost. 2020;10.1111/jth.14964. doi:10.1111/jth.14964

2. Colling M, Sun L, Upadhyay V, Ryu J, Li A, Uhl L, Kaufman RM, Stowell CP, Dzik WH, Makar RS, Bendapudi PK. Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura. Transfusion. 2020;60(4):841‐846. doi:10.1111/trf.15721

3. Upadhyay VA, Geisler BP, Sun L, Uhl L, Kaufman RM, Stowell C, Makar RS, Bendapudi PK. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. Br J Haematol. 2019;186(3):490‐498. doi:10.1111/bjh.15932

4. Sun L, Mack J, Li A, Ryu J, Upadhyay VA, Uhl L, Kaufman RM, Stowell CP, Dzik WS, Makar RS, Bendapudi PK. Predictors of relapse and efficacy of rituximab in immune thrombotic thrombocytopenic purpura. Blood Adv. 2019;3(9):1512‐1518. doi:10.1182/bloodadvances.2019031039

5. Bendapudi PK, Robbins A, LeBoeuf N, et al. Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate. Blood Adv. 2018;2(21):2917‐2921. doi:10.1182/bloodadvances.2018024430

6. Fitzsimons MG, Leaf RK, Mack J, Bendapudi PK, Shen T, Cameron DE. Perioperative management of a redo aortic root replacement in a patient with severe factor XI deficiency. J Card Surg. 2018;33(2):86‐89. doi:10.1111/jocs.13526

7. Colling ME, Bendapudi PK. Purpura Fulminans: Mechanism and Management of Dysregulated Hemostasis. Transfus Med Rev. 2018;32(2):69‐76. doi:10.1016/j.tmrv.2017.10.001

Schulman Lab

1. Schulman S, El-Darzi E, Florido MH, Friesen M, Merrill-Skoloff G, Brake MA, Schuster CR, Lin L, Westrick RJ, Cowan CA, Flaumenhaft R, et al. A coagulation defect arising from heterozygous premature termination of tissue factor [published online ahead of print, 2020 Jul 14]. J Clin Invest. 2020;133780. doi:10.1172/JCI133780

2. Higgins SJ, De Ceunynck K, Kellum JA, Chen X, Gu X, Chaudhry SA, Schulman S, Libermann TA, Lu S, Shapiro NI, Christiani DC, Flaumenhaft R, Parikh SM. Tie2 protects the vasculature against thrombus formation in systemic inflammation. J Clin Invest. 2018;128(4):1471‐1484. doi:10.1172/JCI97488

3. Stolla M, Chang S, Schulman S, Bauer K, Haspel R, Lerner AB. Use of thromboelastography in the management of a patient with acquired von Willebrand disease undergoing cardiac bypass surgery. Br J Haematol. 2018;181(1):143‐145. doi:10.1111/bjh.14511

4. Simeoni I, Stephens JC, Hu F, Deevi SVV, Megy K, Bariana TK, Lentaigne C, Schulman S, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood. 2016;127(23):2791‐2803. doi:10.1182/blood-2015-12-688267

5. Turro E, Greene D, Wijgaerts A, et al. A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. Sci Transl Med. 2016;8(328):328ra30. doi:10.1126/scitranslmed.aad7666

6. Stritt S, Nurden P, Turro E, et al. A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. Blood. 2016;127(23):2903‐2914. doi:10.1182/blood-2015-10-675629